Astellas Unveils New Findings on XOSPATA at ASH 2025, Signifying Hope for AML Patients Astellas Pharma Inc. will showcase new research on XOSPATA™ at the ASH 2025 Annual Meeting, focusing on treatment strategies for FLT3m+ AML patients and outcomes in relapsed cases.

Astellas Unveils New Findings on XOSPATA at ASH 2025, Signifying Hope for AML Patients #XOSPATA #gilteritinib #FLT3m+_AML

Gilternib 40 mg (Gilteritinib) | Online International Pharmacy Gilternib 40 mg (Gilteritinib) is used to treat relapsed or refractory acute myeloid leukemia with FLT3 mutation, targeting cancer cell growth.

Gilternib 40 mg (Gilteritinib) is an oral targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations, inhibiting FLT3 to slow cancer cell growth and spread.
#Gilternib40mg #Gilteritinib #OnlineMedicine #Oncology #Health
jnspharma.com/product/gilt...

Lovely to catch up with David Sallman, who updated us on a Phase I study of CPX-351 plus #gilteritinib in R/R FLT3m #AML, top #MDS highlights from #ASH24 & more! 🎥 💡

Stay tuned for our interviews on vjhemonc.com! 👀

#MDSsm #HemOnc